A prospective, randomized, double-blind, placebo-controlled, single bolus, multinational, multi-center, parallel group, dose-ranging study of desmoteplase (INN) in the indication of acute stroke.

Trial Profile

A prospective, randomized, double-blind, placebo-controlled, single bolus, multinational, multi-center, parallel group, dose-ranging study of desmoteplase (INN) in the indication of acute stroke.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Mar 2012

At a glance

  • Drugs Desmoteplase (Primary)
  • Indications Embolism and thrombosis; Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms DIAS-2
  • Most Recent Events

    • 19 Aug 2011 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
    • 25 Feb 2010 The findings from the post hoc analysis provided the basis for the design of the currently ongoing clinical phase III programme (DIAS-3 and -4).
    • 25 Feb 2010 Data from a post-hoc subgroup analysis have been presented at the International Stroke Conference (ISC), according to a Lundbeck media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top